Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis Savian

Executive Summary

Propentofylline development for Alzheimer's is halted after the Phase IIIb Propentofylline Long-term Use Study demonstrated no difference versus placebo. Aventis was finalizing the protocol for an additional Phase III study in the U.S., slated to begin in early 2000. Aventis' attempt to gain approval in Europe for the glial cell modulator was met with a negative opinion by the Committee for Proprietary Medicinal Products in 1998, which was upheld in 1999 after the company appealed the decision (1"The Pink Sheet" July 26, 1999, p. 18)
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS035687

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel